Collaboration Antigen definition

Collaboration Antigen means, with respect to each Program, the Antigen selected in accordance with Section 4.3; provided, that the Collaboration Antigen shall not be a Cue Reserved Antigen.
View Source
Collaboration Antigen means any Antigen listed as a “Collaboration Antigen” on Exhibit B, as such Exhibit may be amended pursuant to Sections 2.2.1(j), 2.2.1(l), 2.2.2(c), 2.2.2(d), 2.3.1, 2.3.3, 2.6.4, 2.6.5, 4.15, 5.9, 5.11 and 16.8.3(a).
View Source
Collaboration Antigen means the Initial Collaboration Antigen, the Second Collaboration Antigen and any other Antigen so designated pursuant to Sections 4.5.2 or 9.7.
View Source

Examples of Collaboration Antigen in a sentence

  • In such event, ABX shall consult with AZ and ABX shall use Commercially Reasonable Efforts to provide an additional immunogen of such Collaboration Antigen that does not pose such risk.

  • If AZ determines that it is safe for AZ or its sublicensees to pursue the research, development, launch or sale of such Licensed Product in such Major Market(s), then AZ shall have the right to elect not to terminate this Agreement with respect to such Collaboration Antigen and instead continue to Exploit such Licensed Product pursuant to this Agreement.

  • The Parties acknowledge and agree that (i) an Antigen derived from [***] is the Collaboration Antigen for the CUE-101 Program; (ii) LGC has selected [***] as its Initial Collaboration Allele for the CUE-101 Program, and (iii) Cue has selected the [***] Allele as its Initial Collaboration Allele for the CUE-101 Program.

  • Notwithstanding the foregoing, AZ shall have the right to select a Candidate Drug that binds to and is directed against a Collaboration Antigen even before the Research Management Committee issues its recommendation with respect to such Collaboration Antigen.

  • For the avoidance of doubt, such Collaboration Antigen shall not be deemed to be a Discontinued Antigen if AZ provides an Election Notice for at least one Candidate Drug that binds to and is directed against such Collaboration Antigen.

  • Promptly following the designation of an Antigen as a Collaboration Antigen, the Parties shall negotiate in good faith to determine the financial terms on which the license grant to AZ under clause (ii) above shall be made.

  • To the extent known to ABX, ABX shall notify AZ of any such risks with respect to an Antigen prior to its designation as a Proposed Antigen, Prioritized Antigen or Collaboration Antigen, whichever is earlier.

  • If AZ declines to designate such Antigen as a Collaboration Antigen, AZ shall notify ABX in writing and, if ABX wishes to pursue Antibodies or Antibody Equivalents that bind to and are directed against such Antigen, ABX shall provide an Exercise Notice to AZ and such Antigen shall be designated a Discontinued Antigen, but only with respect to those Antibodies that have been offered to AZ either before such Antigen was designated a Failed Antigen or during such [Confidential treatment requested] period.

  • If Cue provides written notice to LGC by [***], that it has selected either [***] as an Antigen for which Cue desires to initiate a Research program (such selected Antigen, a “Cue Selected Antigen”), LGC shall have until [***] (the “CUE-102 Program Early Selection Period”) to select such Cue Selected Antigen as the Collaboration Antigen for the CUE-102 Program.

  • After the first Phase II Completion for a Candidate Drug that binds to and is directed against a Collaboration Antigen (other than a Discontinued Antigen or Failed Antigen), or earlier, at the election of AZ, AZ shall determine whether it wishes to proceed with the further development and commercialization of any Candidate Drug(s) that bind to and are directed against such Collaboration Antigen as a Licensed Product(s) by providing written notice to ABX (an “Election Notice”).


More Definitions of Collaboration Antigen

Collaboration Antigen means each of (i) a human papillomavirus (“HPV”) antigen and (ii) each other Antigen mutually selected by the Parties. For the avoidance of doubt, TCL is not a Collaboration Antigen.
View Source

Related to Collaboration Antigen

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the “dry weight” of the portion taken for analysis. In the case of paints and similar products and other mixtures containing oil or fat the “dry weight” means the dry weight of the material remaining after the substance has been thoroughly mixed and treated with suitable solvents to remove oil, fats, varnish or other media.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.